CUE

Upgrades * B of A Securities upgraded the previous rating for O-I Glass Inc (NYSE: OI) from Neutral to Buy. The current stock performance of O-I Glass shows a 52-week-high of 15.64 and a 52-week-low of 4.305. Moreover, at the end of the last trading period, the closing price was at $11.86. * Goldman Sachs upgraded the previous rating for Nutanix Inc (NASDAQ: NTNX) from Sell to Neutral. Nutanix earned $0.44 in the first quarter, compared to $0.71 in the year-ago quarter. The stock has a 52-week-high of 37.86 and a 52-week-low of 11.31. At the end of the last trading period, Nutanix closed at $28.47. * For General Electric Co (NYSE: GE), Oppenheimer upgraded the previous rating of Perform to the current rating Outperform. General Electric earned $0.06 in the third quarter, compared to $0.15 in the year-ago quarter. The current stock performance of General Electric shows a 52-week-high of 13.26 and a 52-week-low of 5.48. Moreover, at the end of the last trading period, the closing price was at $10.07. * According to B of A Securities, the prior rating for Domtar Corp (NYSE: UFS) was changed from Underperform to Neutral. For the third quarter, Domtar had an EPS of $0.33, compared to year-ago quarter EPS of $0.89. The stock has a 52-week-high of 40.05 and a 52-week-low of 18.4. At the end of the last trading period, Domtar closed at $30.27. * For AerCap Holdings NV (NYSE: AER), B of A Securities upgraded the previous rating of Neutral to the current rating Buy. In the third quarter, AerCap Holdings showed an EPS of $1.24, compared to $2.01 from the year-ago quarter. The current stock performance of AerCap Holdings shows a 52-week-high of 64.86 and a 52-week-low of 10.42. Moreover, at the end of the last trading period, the closing price was at $40.47. * According to Raymond James, the prior rating for Wells Fargo & Co (NYSE: WFC) was changed from Underperform to Outperform. In the third quarter, Wells Fargo showed an EPS of $0.42, compared to $1.07 from the year-ago quarter. The current stock performance of Wells Fargo shows a 52-week-high of 54.75 and a 52-week-low of 20.76. Moreover, at the end of the last trading period, the closing price was at $26.30. * According to Raymond James, the prior rating for Chubb Ltd (NYSE: CB) was changed from Outperform to Strong Buy. Chubb earned $2.00 in the third quarter, compared to $2.70 in the year-ago quarter. The current stock performance of Chubb shows a 52-week-high of 167.74 and a 52-week-low of 87.35. Moreover, at the end of the last trading period, the closing price was at $149.16. * For Ambarella Inc (NASDAQ: AMBA), Summit Insights Group upgraded the previous rating of Hold to the current rating Buy. Ambarella earned $0.09 in the third quarter, compared to $0.32 in the year-ago quarter. The current stock performance of Ambarella shows a 52-week-high of 73.59 and a 52-week-low of 36.02. Moreover, at the end of the last trading period, the closing price was at $66.37. Downgrades * According to Citigroup, the prior rating for Werner Enterprises Inc (NASDAQ: WERN) was changed from Buy to Neutral. In the third quarter, Werner Enterprises showed an EPS of $0.69, compared to $0.57 from the year-ago quarter. The stock has a 52-week-high of 47.43 and a 52-week-low of 28.99. At the end of the last trading period, Werner Enterprises closed at $40.32. * According to Deutsche Bank, the prior rating for ViacomCBS Inc (NASDAQ: VIAC) was changed from Buy to Hold. In the third quarter, ViacomCBS showed an EPS of $0.91, compared to $1.10 from the year-ago quarter. At the moment, the stock has a 52-week-high of 43.04 and a 52-week-low of 10.1. ViacomCBS closed at $34.62 at the end of the last trading period. * For Silgan Holdings Inc (NASDAQ: SLGN), B of A Securities downgraded the previous rating of Neutral to the current rating Underperform. Silgan Hldgs earned $1.04 in the third quarter, compared to $0.76 in the year-ago quarter. The current stock performance of Silgan Hldgs shows a 52-week-high of 40.44 and a 52-week-low of 24.645. Moreover, at the end of the last trading period, the closing price was at $34.58. * According to Citigroup, the prior rating for Schneider National Inc (NYSE: SNDR) was changed from Buy to Neutral. In the third quarter, Schneider National showed an EPS of $0.31, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of 28.13 and a 52-week-low of 15.36. At the end of the last trading period, Schneider National closed at $21.25. * Citigroup downgraded the previous rating for Knight-Swift Transportation Holdings Inc (NYSE: KNX) from Buy to Neutral. For the third quarter, Knight-Swift had an EPS of $0.79, compared to year-ago quarter EPS of $0.48. At the moment, the stock has a 52-week-high of 47.44 and a 52-week-low of 27.54. Knight-Swift closed at $40.96 at the end of the last trading period. * According to B of A Securities, the prior rating for Amcor PLC (NYSE: AMCR) was changed from Neutral to Underperform. For the first quarter, Amcor had an EPS of $0.16, compared to year-ago quarter EPS of $0.13. The stock has a 52-week-high of 12.4 and a 52-week-low of 5.8. At the end of the last trading period, Amcor closed at $11.57. * According to Jefferies, the prior rating for Ulta Beauty Inc (NASDAQ: ULTA) was changed from Buy to Hold. In the second quarter, Ulta Beauty showed an EPS of $0.73, compared to $2.72 from the year-ago quarter. The current stock performance of Ulta Beauty shows a 52-week-high of 304.65 and a 52-week-low of 124.05. Moreover, at the end of the last trading period, the closing price was at $282.87. * According to Deutsche Bank, the prior rating for PACCAR Inc (NASDAQ: PCAR) was changed from Buy to Hold. For the third quarter, PACCAR had an EPS of $1.11, compared to year-ago quarter EPS of $1.75. The current stock performance of PACCAR shows a 52-week-high of 95.82 and a 52-week-low of 49.11. Moreover, at the end of the last trading period, the closing price was at $89.56. * According to BTIG, the prior rating for Fulgent Genetics Inc (NASDAQ: FLGT) was changed from Buy to Neutral. In the third quarter, Fulgent Genetics showed an EPS of $2.08, compared to $0.14 from the year-ago quarter. The current stock performance of Fulgent Genetics shows a 52-week-high of 52.47 and a 52-week-low of 6.7. Moreover, at the end of the last trading period, the closing price was at $43.60. * Credit Suisse downgraded the previous rating for Baozun Inc (NASDAQ: BZUN) from Outperform to Neutral. In the third quarter, Baozun showed an EPS of $0.22, compared to $0.14 from the year-ago quarter. The current stock performance of Baozun shows a 52-week-high of 47.51 and a 52-week-low of 22.19. Moreover, at the end of the last trading period, the closing price was at $38.64. Initiations * With a current rating of Market Perform, BMO Capital initiated coverage on Southern Co (NYSE: SO). The price target seems to have been set at $67.00 for Southern. In the third quarter, Southern showed an EPS of $1.22, compared to $1.34 from the year-ago quarter. At the moment, the stock has a 52-week-high of 71.1 and a 52-week-low of 41.96. Southern closed at $60.44 at the end of the last trading period. * BMO Capital initiated coverage on Duke Energy Corp (NYSE: DUK) with an Outperform rating. The price target for Duke Energy is set to $99.00. In the third quarter, Duke Energy showed an EPS of $1.87, compared to $1.79 from the year-ago quarter. The stock has a 52-week-high of 103.79 and a 52-week-low of 62.13. At the end of the last trading period, Duke Energy closed at $93.34. * Berenberg initiated coverage on Cue Biopharma Inc (NASDAQ: CUE) with a Buy rating. The price target for Cue Biopharma is set to $30.00. For the third quarter, Cue Biopharma had an EPS of $0.34, compared to year-ago quarter EPS of $0.31. The stock has a 52-week-high of 31.69 and a 52-week-low of 9.3. At the end of the last trading period, Cue Biopharma closed at $12.01. * Berenberg initiated coverage on Black Diamond Therapeutics Inc (NASDAQ: BDTX) with a Buy rating. The price target for Black Diamond Therapeutic is set to $58.00. In the third quarter, Black Diamond Therapeutic showed an EPS of $0.50, compared to $4.50 from the year-ago quarter. At the moment, the stock has a 52-week-high of 46.25 and a 52-week-low of 17.63. Black Diamond Therapeutic closed at $33.54 at the end of the last trading period. * For Atea Pharmaceuticals Inc (NASDAQ: AVIR), William Blair initiated coverage, by setting the current rating at Outperform. At the moment, the stock has a 52-week-high of 34.81 and a 52-week-low of 31.5. Atea Pharmaceuticals closed at $33.54 at the end of the last trading period. * With a current rating of Buy, Berenberg initiated coverage on Arcus Biosciences Inc (NYSE: RCUS). The price target seems to have been set at $50.00 for Arcus Biosciences. In the third quarter, Arcus Biosciences showed an EPS of $0.03, compared to $0.51 from the year-ago quarter. The current stock performance of Arcus Biosciences shows a 52-week-high of 37.41 and a 52-week-low of 7.69. Moreover, at the end of the last trading period, the closing price was at $25.80. * With a current rating of Equal-Weight, Morgan Stanley initiated coverage on 2U Inc (NASDAQ: TWOU). The price target seems to have been set at $39.00 for 2U. 2U earned $0.24 in the third quarter, compared to $0.41 in the year-ago quarter. The stock has a 52-week-high of 49.46 and a 52-week-low of 11.51. At the end of the last trading period, 2U closed at $34.31. * HC Wainwright & Co. initiated coverage on Curis Inc (NASDAQ: CRIS) with a Buy rating. The price target for Curis is set to $5.00. Curis earned $0.11 in the third quarter, compared to $0.19 in the year-ago quarter. The current stock performance of Curis shows a 52-week-high of 3.59 and a 52-week-low of 0.62. Moreover, at the end of the last trading period, the closing price was at $1.35. * KeyBanc initiated coverage on Workday Inc (NASDAQ: WDAY) with an Overweight rating. The price target for Workday is set to $251.00. In the third quarter, Workday showed an EPS of $0.86, compared to $0.53 from the year-ago quarter. The stock has a 52-week-high of 248.75 and a 52-week-low of 107.75. At the end of the last trading period, Workday closed at $207.10. * With a current rating of Overweight, KeyBanc initiated coverage on Oracle Corp (NYSE: ORCL). The price target seems to have been set at $65.00 for Oracle. Oracle earned $0.93 in the first quarter, compared to $0.81 in the year-ago quarter. The current stock performance of Oracle shows a 52-week-high of 62.5999 and a 52-week-low of 39.71. Moreover, at the end of the last trading period, the closing price was at $56.11. * With a current rating of Overweight, KeyBanc initiated coverage on ServiceNow Inc (NYSE: NOW). The price target seems to have been set at $620.00 for ServiceNow. ServiceNow earned $1.21 in the third quarter, compared to $0.99 in the year-ago quarter. At the moment, the stock has a 52-week-high of 537.53 and a 52-week-low of 238.93. ServiceNow closed at $522.70 at the end of the last trading period. * KeyBanc initiated coverage on Microsoft Corp (NASDAQ: MSFT) with an Overweight rating. The price target for Microsoft is set to $250.00. For the first quarter, Microsoft had an EPS of $1.82, compared to year-ago quarter EPS of $1.38. The current stock performance of Microsoft shows a 52-week-high of 232.86 and a 52-week-low of 132.52. Moreover, at the end of the last trading period, the closing price was at $210.11. * With a current rating of Overweight, KeyBanc initiated coverage on Salesforce.com Inc (NYSE: CRM). The price target seems to have been set at $310.00 for Salesforce.com. For the second quarter, Salesforce.com had an EPS of $1.44, compared to year-ago quarter EPS of $0.66. The stock has a 52-week-high of 284.5 and a 52-week-low of 115.29. At the end of the last trading period, Salesforce.com closed at $257.58. * With a current rating of Buy, Goldman Sachs initiated coverage on Lufax Holding Ltd (NYSE: LU). The price target seems to have been set at $20.00 for Lufax Holding. The stock has a 52-week-high of 19.56 and a 52-week-low of 13.01. At the end of the last trading period, Lufax Holding closed at $15.07. * Evercore ISI Group initiated coverage on BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) with an Outperform rating. The price target for BioCryst Pharmaceuticals is set to $12.00. BioCryst Pharmaceuticals earned $0.26 in the third quarter, compared to $0.34 in the year-ago quarter. The stock has a 52-week-high of 6.2862 and a 52-week-low of 1.58. At the end of the last trading period, BioCryst Pharmaceuticals closed at $4.40. * For Datadog Inc (NASDAQ: DDOG), KeyBanc initiated coverage, by setting the current rating at Sector Weight. For the third quarter, Datadog had an EPS of $0.05, compared to year-ago quarter EPS of $0.00. At the moment, the stock has a 52-week-high of 118.13 and a 52-week-low of 28.88. Datadog closed at $91.04 at the end of the last trading period. * For Alteryx Inc (NYSE: AYX), KeyBanc initiated coverage, by setting the current rating at Sector Weight. In the third quarter, Alteryx showed an EPS of $0.39, compared to $0.24 from the year-ago quarter. The stock has a 52-week-high of 185.75 and a 52-week-low of 75.17. At the end of the last trading period, Alteryx closed at $113.05. * KeyBanc initiated coverage on Splunk Inc (NASDAQ: SPLK) with an Overweight rating. For the second quarter, Splunk had an EPS of $0.33, compared to year-ago quarter EPS of $0.67. The stock has a 52-week-high of 225.8944 and a 52-week-low of 93.92. At the end of the last trading period, Splunk closed at $198.11. * For Palo Alto Networks Inc (NYSE: PANW), KeyBanc initiated coverage, by setting the current rating at Overweight. Palo Alto Networks earned $1.62 in the first quarter, compared to $1.05 in the year-ago quarter. The current stock performance of Palo Alto Networks shows a 52-week-high of 296.71 and a 52-week-low of 125.47. Moreover, at the end of the last trading period, the closing price was at $296.12.See more from Benzinga * Click here for options trades from Benzinga * Understanding American Airlines Group's Unusual Options Activity * Analyzing Camping World Holdings's Unusual Options Activity(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that it participated in a pre-recorded fireside chat as part of the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held on December 1-3, 2020. The pre-recorded presentation will be available to participants during the conference and on the Events page of the Investors & Media section of the Company’s website www.cuebiopharma.com beginning today, November 23, 2020 at 10:00 a.m. EST. An archived version of the recording will be accessible for 90 days following the event.About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.Investor Contact George B. Zavoico, Ph.D. VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.comMedia Contact Alison Chen LifeSci Communications achen@lifescicomms.com

CAMBRIDGE, Mass., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, announced today that the company has extended the term of the research program under its existing 2017 research collaboration and license agreement with Merck toward developing a clinical candidate for the treatment of type 1 diabetes and an additional undisclosed autoimmune disease. “We are very pleased with the progress to date in our ongoing strategic collaboration with Merck,” said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. “Extending the research term of our agreement based on promising preclinical data with a goal of identifying a clinical candidate underscores the significant potential of our therapeutic Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform and CUE-300 series in the treatment of debilitating autoimmune diseases.”Under the terms of the extension, Cue Biopharma will receive additional financial research support to further study and develop promising preclinical biologics with the objective of identifying clinical candidates.Cue Biopharma entered into an exclusive patent license and research collaboration agreement with Merck in November 2017 to develop biologics for the treatment of selected autoimmune diseases. For further information regarding the amendment, please refer to the Current Report on Form 8-K to be filed by Cue Biopharma with the SEC on November 19, 2020.About Immuno-STAT Immuno-STAT™ biologics are being designed for targeted modulation of disease-associated T cells in the areas of immuno-oncology and autoimmune disease. Each of our biologic drug candidates is designed using our proprietary scaffold comprising: 1) a peptide-MHC complex (pMHC) to provide selectivity through interaction with the T cell receptor (TCR), and 2) a unique co-stimulatory signaling molecule to modulate the activity of the target T cells.The simultaneous engagement of co-regulatory molecules and pMHC binding mimics the signals delivered by antigen presenting cells (APCs) to T cells during a natural immune response. This design enables Immuno-STAT biologics to engage with the T cell population of interest, resulting in highly targeted T cell modulation. Because our drugs are delivered directly in the patient’s body (in vivo), they are fundamentally different from other T cell therapeutic approaches that require the patients’ T cells to be extracted, modified outside the body (ex vivo), and reinfused.About Cue Biopharma Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) is designed to harness the body’s intrinsic immune system without the need for ex vivo manipulation.Headquartered in Cambridge, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in the design and clinical development of protein biologics, immunology and immuno-oncology.For more information, visit www.cuebiopharma.com and follow us on Twitter https://twitter.com/CueBiopharma.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the goal of identifying a clinical candidate under the Merck collaboration; the potential of the Immuno-STAT platform and CUE-300 series to treat autoimmune diseases; the anticipated results of the company’s drug development efforts, including study results; and the company’s expectations regarding regulatory developments and expected future operating results. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the company’s limited operating history, limited cash and a history of losses; the company’s ability to achieve profitability; potential setbacks in the company’s research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (“FDA”) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the company’s operations and clinical trials; negative or inconclusive results from the company’s clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company’s reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company’s ability to obtain adequate financing to fund its business operations in the future; ; the company’s ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.Investor Contact George B. Zavoico, Ph.D. VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.comMedia Contact Alison Chen LifeSci Communications achen@lifescicomms.com

Cue Biopharma ([[CUE]] +11.3%) says its lead asset CUE-101 currently in ongoing Phase 1 monotherapy dose escalation trial in HPV+ head and neck cancer, has completed dosing cohort 6, at

Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.34) per share. This is a 9.68 percent decrease over losses of $(0.31) per share from the same period last year. The company reported $704.00 thousand in sales

The last three months have been tough on Cue Biopharma, Inc. (NASDAQ:CUE) shareholders, who have seen the share price...

How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

Appointment augments board capabilities with a seasoned business development executive as Cue Biopharma executes its next stage of corporate developmentCAMBRIDGE, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel